Literature DB >> 34914065

Production of Oral Vaccines Based on Virus-Like Particles Pseudotyped with Protozoan-Surface Proteins.

Lucía Lara Rupil1,2, Marianela Del Carmen Serradell1,3, Hugo Daniel Luján4,5.   

Abstract

Giardia lamblia is the only known parasite that can inhabit the harsh upper gastrointestinal tract, where most of the digestive proteases are secreted. Intestinal and free-living protozoa express surface proteins containing an extraordinarily high percentage of cysteine. These cysteine-rich variant-specific surface proteins (VSPs) form a dense coat on the entire surface of Giardia trophozoites, that coat protects the parasite inside the host intestine. VSPs not only are resistant to proteolytic digestion, extreme pH and temperatures, but also stimulate host immune responses. These properties can be used to protect as well as to increase the immunogenicity of vaccine antigens for oral administration. The incorporation of VSPs onto virus-like particles bearing viral antigens allows oral administration of these vaccines, protecting the antigens from degradation and generating robust and protective immune responses. In this chapter we describe the development of this versatile vaccine platform for the generation of safe, stable, and efficient oral vaccines, including their production and validation, as well as the characterization of immune response to oral immunization.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Giardia lamblia; Oral vaccines; Protozoan-surface proteins; Variant-specific surface proteins (VSPs); Virus-like particles

Mesh:

Substances:

Year:  2022        PMID: 34914065     DOI: 10.1007/978-1-0716-1884-4_26

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  25 in total

1.  A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques.

Authors:  Pierre Garrone; Anne-Catherine Fluckiger; Philippe E Mangeot; Emmanuel Gauthier; Pia Dupeyrot-Lacas; Jimmy Mancip; Arnaud Cangialosi; Isaure Du Chéné; Roger LeGrand; Isabelle Mangeot; Dimitri Lavillette; Bertrand Bellier; François-Loic Cosset; Frederic Tangy; David Klatzmann; Charlotte Dalba
Journal:  Sci Transl Med       Date:  2011-08-03       Impact factor: 17.956

2.  Using Protozoan Surface Proteins for Effective Oral Vaccination.

Authors:  Lucía Lara Rupil; Marianela Del Carmen Serradell; Hugo Daniel Luján
Journal:  Trends Parasitol       Date:  2019-07-27

3.  Disruption of antigenic variation is crucial for effective parasite vaccine.

Authors:  Fernando D Rivero; Alicia Saura; Cesar G Prucca; Pedro G Carranza; Alessandro Torri; Hugo D Lujan
Journal:  Nat Med       Date:  2010-04-25       Impact factor: 53.440

4.  Antigenic variation in Giardia lamblia is regulated by RNA interference.

Authors:  César G Prucca; Ileana Slavin; Rodrigo Quiroga; Eliana V Elías; Fernando D Rivero; Alicia Saura; Pedro G Carranza; Hugo D Luján
Journal:  Nature       Date:  2008-12-11       Impact factor: 49.962

Review 5.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

6.  Caveolin-1 interacts with the Gag precursor of murine leukaemia virus and modulates virus production.

Authors:  Zheng Yu; Christiane Beer; Mario Koester; Manfred Wirth
Journal:  Virol J       Date:  2006-09-06       Impact factor: 4.099

7.  Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses.

Authors:  Judit Szécsi; Bertrand Boson; Per Johnsson; Pia Dupeyrot-Lacas; Mikhail Matrosovich; Hans-Dieter Klenk; David Klatzmann; Viktor Volchkov; François-Loïc Cosset
Journal:  Virol J       Date:  2006-09-03       Impact factor: 4.099

8.  Vaccination of domestic animals with a novel oral vaccine prevents Giardia infections, alleviates signs of giardiasis and reduces transmission to humans.

Authors:  Marianela C Serradell; Alicia Saura; Lucia L Rupil; Pablo R Gargantini; Marcela I Faya; Paulina J Furlan; Hugo D Lujan
Journal:  NPJ Vaccines       Date:  2016-09-15       Impact factor: 7.344

9.  Recent advancements in combination subunit vaccine development.

Authors:  Ming Tan; Xi Jiang
Journal:  Hum Vaccin Immunother       Date:  2017-01-02       Impact factor: 3.452

10.  Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins.

Authors:  Marianela C Serradell; Lucía L Rupil; Román A Martino; César G Prucca; Pedro G Carranza; Alicia Saura; Elmer A Fernández; Pablo R Gargantini; Albano H Tenaglia; Juan P Petiti; Renata R Tonelli; Nicolás Reinoso-Vizcaino; José Echenique; Luciana Berod; Eliane Piaggio; Bertrand Bellier; Tim Sparwasser; David Klatzmann; Hugo D Luján
Journal:  Nat Commun       Date:  2019-01-21       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.